Home >

Watson Biological Listing Only Half A Year &Nbsp; Three Major Vaccine Projects Sudden Abortion

2011/5/17 8:36:00 35

??? 日本語 Fran?ais English 中文

Watson'S Biological Vaccine Project Abortion

Once "overhead"

Gem

The first high issue price -- 95 yuan, "foot" 133.8 times IPO price earnings ratio of Watson biological (300142, closing price of 63.43 yuan), after listing half a year suddenly gave investors a head start, the company and GlaxoSmithKline, Changchun Huapu and Guangzhou Shen Yi cooperation four vaccine projects three confirmed failure, cooperation

contract

Or to terminate or terminate.

The three major vaccine projects are terminated at the same time

Watson biology today

Notice

A wholly owned subsidiary, Watson, Jiangsu, has received a letter from the GlaxoSmithKline Co. It is notified of its cooperation with the Mori Ko company Watson Glenn gall vaccine project in Jiangsu. Following the promulgation and implementation of the People's Republic of China Pharmacopoeia (2010 Edition), the State Food and drug administration has not approved the import and filling of the measles mumps rubella vaccine (MMR) in China because of the antibiotics.

GlaxoSmithKline Co believes that the prerequisites for the "cooperation agreement" have not been fully achieved.

Therefore, the "cooperation agreement" should be terminated according to the relevant provisions, and the negotiations on assets acquisition of Watson Glen cooperation project shall be terminated.

At the same time, Watson bio announces that the PIKA nasal mucosal immune vaccine for influenza vaccine developed by the company in cooperation with Guangzhou Shen Yi has been examined by the Scientific Committee of the company, and the results of the project research failed to achieve the expected goal.

After consultation, the two sides signed the agreement on cancelling the contract and agreed to terminate the cooperative contract and related supplementary memorandum. After the termination of the contract, the company will stop the development of PIKA nasal mucosal influenza vaccine.

In addition, Watson bio worked with Changchun Huapu to conduct research on the role of synthetic single chain oligonucleotide enhancing rabies vaccine efficacy and the role of synthetic single chain oligonucleotide in enhancing the efficacy of hepatitis B vaccine. Among them, the effect of synthetic single chain oligonucleotide enhanced rabies vaccine efficacy was considered by the Scientific Committee of the company, and the research results failed to achieve the expected goal.

The two sides revise the agreement and agree to stop the project cooperation of "synthetic single chain oligonucleotide enhancing the efficacy of rabies vaccine", and continue to study the project of "synthetic single chain oligonucleotide enhancing the efficacy of hepatitis B vaccine".

Investors blame the company for its lack of integrity.

Only six months after listing, the three major vaccine research projects will be terminated. This makes the investors of the company somewhat unprepared.

Statistics show that the time of cooperation between Watson and GlaxoSmithKline in Jiangsu is October 5, 2009, the time of cooperation with Guangzhou's Shen Yi is February 21, 2008, and the time of cooperation with Changchun Huapu is even longer, in April 26, 2006.

In addition, the company emphasized in the prospectus that the rabies vaccine was described as "filling the international gap".

Reporters in the stock bar to see, many investors have shouted "limit" slogan, more excited people directly refer to the company "no integrity", "in the stock market, how many reserves, how to ensure growth in the future, and for this purpose has reached a high price of money.

Less than a year before the listing, the announcement was cancelled. From the company's initial mention that new products were listed at the end of 2010, it is now said that the market will be available before the end of 2011. It can be seen from a pile that the company has no credibility whatsoever.

In addition to the announcement of the project termination notice, Watson bio also disclosed the pledge of the third largest shareholder of Yuxi real estate.

In February 17th and April 25th this year, Yuxi real estate mortgaged 3 million and 525 thousand restricted shares of the company to Yuxi commercial bank and Shanghai Pudong Development Bank Yuxi branch as loan guarantee.

Investors can't help asking, "what is the" unique gene "of Watson, who once threatened that" Hai Rui is the only Watson and the only one "and" Watson is a unique gene Watson "?